Manufacturer
Janssen
Contents
Methylphenidate HCl
Indication
Treatment of attention deficit hyperactivity disorder (ADHD). The efficacy of Concerta in the treatment of ADHD was established in controlled trials of children and adolescents 6-17 years and adults 18-65 years who met DSM-IV criteria for ADHD.
Concerta should be used as a part of a comprehensive treatment program where remedial measures alone prove insufficient. A comprehensive treatment program for the treatment of ADHD may include other measures (psychological, educational, social) for patients with this disorder. Diagnosis must be made according to DSM-IV criteria or the guidelines in ICD-10 and should be based on a complete history and evaluation of the patient.
Concerta treatment is not indicated in all patients with ADHD and the decision to use the drug must be based on a very thorough assessment of the severity of the patient's symptoms. Stimulants are not intended for use in the patient who exhibit symptoms secondary to environmental factors and/or other primary psychiatric disorders, including psychosis. Appropriate educational placement is essential and psychosocial intervention is often helpful.
Specific etiology of this syndrome is unknown and there is no single diagnostic test. Adequate diagnosis requires the use of medical and special psychological, educational and social resources. Learning may or may not be impaired.
Instruction
May be taken with or without food: Swallow whole, do not divide/chew/crush.
Drug interaction
MAOIs. Vasopressor agents; coumarin anticoagulants, anticonvulsants, TCAs, SSRIs. Clonidine & centrally acting α2-agonists.
Malaysia
